BioCardia, Inc. (BCDA) AI Stock Analysis

BioCardia, Inc. is a clinical-stage regenerative medicine company focused on cardiovascular and pulmonary diseases. Its primary candidate is the CardiAMP Cell Therapy System, designed to treat heart failure and chronic myocardial ischemia. The company is also evaluating allogeneic cell therapies using investigational bone marrow-derived mesenchymal cells in Phase I/II trials for ischemic systolic heart failure. In addition to biotherapies, BioCardia develops the Helix biotherapeutic delivery system for direct heart muscle delivery and Morph deflectable guides and sheaths for minimally invasive procedures. BioCardia also has a collaboration agreement with CellProthera SAS to develop ProtheraCytes for acute myocardial infarction.

BioCardia has experienced volatile and declining top-line results, with a 5-year revenue CAGR of -39.4% from FY2019 to FY2024. Revenue rose to $1.0M in FY2021 and peaked at $1.4M in FY2022 before falling 64.7% to $477,000 in FY2023 and falling 87.8% to $58,000 in FY2024. Operating margins remained deeply negative throughout, reaching -13794.8% in FY2024 as research and development expense stood at $4.4M. Net losses were -$11.6M in FY2023 and -$7.9M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 100.0% year-over-year, leaving trailing twelve month revenue at $0 and diluted EPS at -$0.64.

As of June 30, 2026, BioCardia held $4.1M in cash and short-term investments and $293,000 in total debt, resulting in net cash of $3.8M. Total assets stood at $4.8M against shareholders' equity of $2.7M. The company reported a current ratio of 2.09 and a debt-to-equity ratio of 0.11. Operating cash flow was -$8.0M and free cash flow was -$8.0M in FY2024, while capital expenditures were $7,000 in FY2025. Over five years, the company's share count increased by 962.9%.

BioCardia has a market capitalization of $13.9M and an enterprise value of $12.1M. The stock trades at an EV-to-revenue multiple of 23.8x and a price-to-book ratio of 5.9x. By comparison, the median of its US-listed Healthcare peers trades at an EV-to-EBITDA multiple of 12.0x and a price-to-sales multiple of 4.1x. BioCardia shares closed at $0.92 on October 16, 2026, down 36.6% over the prior year and down 97.9% over five years, compared to gains of 16.8% and 83.0% for the S&P 500 (SPY).

Wall Street coverage on BioCardia consists of 2 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $15.50, which is 1584.8% above the last close of $0.92. For the fiscal year ending December 31, 2026, the consensus estimate projects an EPS of -$0.71 and revenue of $0. For the following fiscal year, 1 analyst projects an EPS of -$0.58 on revenue of $0. BioCardia beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of BioCardia, Inc. (BCDA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BCDA income statement, BCDA balance sheet, BCDA key metrics, BCDA analyst forecast, BCDA chart. See the BCDA stock overview for the latest quote and news.